<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="328">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04839315</url>
  </required_header>
  <id_info>
    <org_study_id>21-000501</org_study_id>
    <nct_id>NCT04839315</nct_id>
  </id_info>
  <brief_title>COVID-19 Vaccination in Rheumatic Disease Patients</brief_title>
  <official_title>Immunological Consequences of COVID-19 Vaccination in Patients With Rheumatic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research is being done to study the immune responses to COVID-19 vaccination in patients&#xD;
      with rheumatic diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Because patients treated with immunosuppressive agents have been excluded from initial&#xD;
      clinical trials, and most patients with rheumatic diseases are taking immunosuppressants, the&#xD;
      immune responses towards the mRNA COVID19 vaccines in these patients remains unknown. The&#xD;
      goal is to study the immune response to COVID-19 vaccination in patients with rheumatic&#xD;
      diseases. Blood samples collected before and longitudinally after mRNA-based COVID-19&#xD;
      vaccination (i.e., Pfizer and Moderna vaccines) will enable detailed immunological&#xD;
      investigation of the interaction between COVID-19 vaccination and rheumatic diseases. These&#xD;
      efforts will provide novel insights into the COVID-19 vaccine response in patients with&#xD;
      rheumatic diseases, and eventually would inform clinical management to improve patient care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Humoral responses towards mRNA COVID-19 vaccines</measure>
    <time_frame>2 weeks to 6 months after second dose of vaccine</time_frame>
    <description>We aim to examine SARS-Cov2 specific antibody, and autoantibody generation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular immune responses towards mRNA COVID-19 vaccines</measure>
    <time_frame>2 weeks to 6 months after second dose of vaccine</time_frame>
    <description>measurement of immune cell distributions, type I interferon activity, and SARS-Cov2 specific T cell responses</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Sjogren's Syndrome</condition>
  <condition>Inflammatory Myositis</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Gout</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Arthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis)</condition>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>mRNA COVID19 vaccines</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>mRNA-based COVID19 vaccines</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA COVD19 vaccine</intervention_name>
    <description>Subjects will receive two doses of mRNA based COVID19 vaccines.</description>
    <arm_group_label>mRNA COVID19 vaccines</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Rheumatologist confirmed diagnosis of one of the following diagnoses:&#xD;
&#xD;
          -  Systemic lupus erythematosus;&#xD;
&#xD;
          -  Sjogren syndrome;&#xD;
&#xD;
          -  Inflammatory myositis;&#xD;
&#xD;
          -  Psoriatic arthritis;&#xD;
&#xD;
          -  Osteoarthritis;&#xD;
&#xD;
          -  Gout;&#xD;
&#xD;
          -  Ankylosing spondylitis;&#xD;
&#xD;
          -  IBD-related arthritis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active infection or untreated malignancy (other than skin cancer) at enrollment.&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hu Zeng, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane M Jaquith</last_name>
      <phone>507-284-4502</phone>
      <email>jaquith.jane@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Hu Zeng</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

